Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Actually, the total neutropenia market was $3.3B in the third Q of 2019. Coherus mentioned during their 3rd Q 2019 earnings CC that Neulasta had 75% of the market. We also know Neulasta sales came in at $619M so that means the total market was 3.3B. So the SPPI Presentation slide that indicates the market is greater than $3B is not fiction.

In my previous post I was guessing that w Neulasta sales of 583M, down 5.8% from the previous Q, Neulasta’s market share was 69% in the 4thQ

I'm using Neulasta as a rough yardstick in coming up w a projection

but that can’t be right because if I did the same calculation as above using $583M and 69% market share I would get a total neutropenia market of 3.4B. I would guess that the total market has slipped some although here’s an interesting comment from the Coherus CC

I would also note that we have seen growth in the overall pegfilgrastim marketplace, suggesting that biosimilar entrants have increased patient access.

If I use 73% as my denominator, I get a total market of $3.2B. So it seems Neulasta still has ~73% market share plus or minus 1% and Spectrum can keep on using that slide in their Presentation.